Market Overview
The global Neutropenia Treatment market was valued at USD 16.25 billion in 2025 and is projected to reach USD 26.46 billion by 2033, growing at a CAGR of 5.6% during the forecast period from 2026 to 2033.
Neutropenia is a disorder in which the number of circulating neutrophils, a type of white blood cell found in the blood, is abnormally low. The bulk of circulating lymphocytes is these cells, which help protect the body from infections caused by bacteria, viruses, and other harmful organisms. A drop in neutrophil levels in the blood makes a patient more susceptible to infection and fatal. As a result, prevention is required right away.
Market Scope
| Metrics | Details |
| Market CAGR | 5.6% |
| Segments Covered | By Treatment, By Dosage Form, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights - Download Sample
Market Dynamics
Neutropenia Treatment Market growth is driven by is the development of new treatments in conjunction with an increase in cases of chemotherapy-induced neutropenia. Furthermore, the novel drug delivery strategy increases patient convenience, resulting in greater adherence to the patient and, as a result, stimulating market growth.
The Increasing in research and development and development of new drugs will drive the market growth
The neutropenia treatment industry is expected to grow significantly due to major industry players supporting research and development as well as public awareness of neutropenia therapy. As major market tactics, companies in this market are focusing on increasing knowledge about preventive measures, early diagnosis, and effective treatment of neutropenia. The introduction of small molecules is one of the new developments gaining traction in the global neutropenia treatment market. Beyond Spring Pharmaceuticals' development of Plinabulin, a small molecule with immune-boosting properties, is expected to revolutionize neutropenia treatment. In addition to immune-boosting effects, Phase II studies have revealed that this molecule has far more beneficial anti-cancer effects. There is currently a high demand for cost-effective drugs in the neutropenia treatment market. As a result, vendors concentrate on producing small molecules with lower processing costs than biologics. Amgen introduced the Neulasta (Pegfilgrastim) Delivery Kit in April 2017. This kit is a novel drug delivery method that allows for the self-administration of Neulasta, which aids in the stimulation of white blood cell production.
Moreover, chemotherapy is commonly used to target neoplastic cells. However, while this therapy is effective against most cancers, the cells of the hematopoietic system, which produces billions of blood cells needed daily, are highly sensitive to it, resulting in blood cell population loss. Chemotherapy-induced neutropenia is the medical term for this condition. In chemotherapy-induced neutropenia, the body has a low level of neutrophils, which are types of white blood cells. According to the Lancet Oncology journal, chemotherapy was used by 58 percent of new cancer patients (9.8 million out of 17 million) worldwide in 2018. According to the report, the number of new cancer cases will rise to 26 million by 2040, with chemotherapy accounting for 53 percent (15 million out of 26 million) of the total (an estimated 5.2 million new cancer cases). Eastern Asia would house more than one-third of the 15 million people who would require chemotherapy in 2040. (5.2 million, 35 percent ).These factors will drive the growth of neutropenia treatment market.
The patent expiration of the most preferred drugs is likely to hamper the market growth
Chemotherapy is the most commonly used cancer treatment. The rising use of chemotherapy will propel the chemotherapy-induced neutropenia treatment market forward. However, market revenue is expected to decrease due to the patent expiration of the most preferred drugs to treat chemotherapy-induced neutropenia and the emergence of various biosimilars. However, as biosimilars become more common, this condition will be balanced.
Market Geographical Share
North America region holds the largest market share of the global neutropenia treatment market
North America is anticipated to dominate the neutropenia treatment market, globally. The factors attributed to the high growth of the region are due to increase in the prevalence of various types of cancer, an increase in government research funding, and an increase in cases of chemotherapy-induced side effects among cancer survivors. According to World Health Organization, cancer is the leading cause of death globally, accounting for nearly 10 million deaths in 2020, or nearly one in every six deaths. The most common cancers are breast, lung, colon, rectal, and prostate cancer. Tobacco use, a high BMI, alcohol consumption, a lack of fruits and vegetables, and physical activity account for roughly one-third of cancer deaths. Infections that cause cancer, such as human papillomavirus (HPV) and hepatitis, account for approximately 30% of cancer cases in low- and lower-middle-income countries.
Furthermore, organic and inorganic strategies such as mergers and acquisitions and partnerships among key market players will strengthen their product portfolios in the studied market, driving the market. In addition, several product launches in the market will lead to profitable market growth. For instance, in Februray 2018, Partner Therapeutics, a Boston-based cancer company, paid $60 million for Sanofi's Leukine (Sargramostim). Leukine is the only FDA-approved recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of acute myelogenous leukemia (AML) in older adults, and it is used in both allogeneic and autologous bone marrow transplantation. Furthermore, advancements in various neutropenia treatment from established key players, in the United States, are likely to drive the market growth in North America.
Key Developments
February 2026: Growing adoption of colony-stimulating factors (G-CSFs) and long-acting biologics improved neutrophil recovery and reduced infection risks in neutropenia patients.
January 2026: Increasing focus on biosimilar drugs enhanced treatment affordability and expanded patient access to neutropenia therapies across global markets.
December 2025: Rising advancements in targeted therapies and next-generation biologics accelerated innovation in chemotherapy-induced neutropenia management.
November 2025: Expansion of home-based care and self-administered injectable treatments improved patient convenience and reduced hospital dependency.
October 2025: Increasing prevalence of cancer and chemotherapy treatments boosted demand for effective neutropenia therapies worldwide.
September 2025: Growing integration of antibiotics and antifungals as prophylactic and therapeutic options strengthened infection management in neutropenia patients.
August 2025: Rising investments in clinical research and pipeline drugs supported development of innovative therapies for severe and chronic neutropenia conditions.
July 2025: Increasing awareness of chemotherapy-related side effects and improved diagnostic capabilities encouraged early detection and adoption of preventive treatments globally.
Market Companies and Competitive Landscape
The neutropenia treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc, Novartis AG, Pfizer Inc, Kyowa Kirin Co Ltd(Kirin Company), Dr.Reddy, Intas Pharmaceuticals among others.
Kyowa Kirin Co Ltd
Overview:
Kyowa Kirin is a life science R&D company with a focus on biotechnology. The Kyowa Kirin Group companies strive to improve people's health and well-being worldwide by creating new value through advances in life sciences and technology.
Product Portfolio:
GRAN: GRAN® (Filgrastim) is a human colony-stimulating factor (G-CSF) created through genetic recombination. It works by selectively increasing the number of a type of white blood cell known as neutrophils and their functional efficacy. This allows for a faster recovery from neutropenia caused by cancer chemotherapy and reduces the risk of infection, allowing for more effective chemotherapy. It also works to treat congenital and neutropenia caused by hematopoietic stem-cell transplantation (such as bone-marrow transplants). It received approval for PBSCT (peripheral blood stem cell transfusion) mobilization.
